Handelsavisen
prelaunch
Companies Real Estate LH.BK
LH
LH.BK SET (Bangkok) Real Estate Rental, Development & Operations

Land and Houses PCL

$3,68
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
6,94 %
Op margin
13,8 %
ROE
7,2 %
Net margin
17,9 %
Debt / equity
1,53
Beta
52w range
Volume
Day range
Prev close
$315,53
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Land and Houses PCL operates in the real estate rental, development, and operations industry, generating revenue primarily through property development and management activities.

Business. Land and Houses PCL (LH.BK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorReal Estate
IndustryReal Estate Rental, Development & Operations
Generated · model-assisted
Sell-side consensus
HOLD13 analysts
1 buy8 hold4 sell
Avg 12m price target3,86

Analyst recommendations

13 analysts · consensus Hold
Buy1
Hold8
Sell4
12-month price target
3,86
Consensus of sell-side coverage.
Upcoming events
  • DividendDividend USD 0.72/sh2026-09-11
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
13 analysts · indicative
Ownership
not yet wired
Profitability
7,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate · THIS SECTOR−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LH.BK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Land and Houses PCL (LH.BK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorReal Estate
    IndustryReal Estate Rental, Development & Operations
    AI synthesis
    GENERATED

    Land and Houses PCL maintains a debt-to-equity ratio of 1.53, indicating a moderate reliance on debt financing, which is in line with the industry norms for real estate firms. The company's liquidity position is characterized as medium, with a current ratio of 1.95, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is negative at -2.57 billion THB, reflecting ongoing capital expenditures of -4.57 billion THB, which are typical for a development-focused real estate company.

    Profitability metrics show a return on equity (ROE) of 7.16% and a return on assets (ROA) of 2.64%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming in terms of asset and equity utilization compared to its peers. The operating margin of 13.77% (calculated from operating income of 2.86 billion THB on revenue of 20.75 billion THB) is in line with the industry average, but the net profit margin of 17.90% is slightly above average, suggesting effective cost control in the operating and pre-tax phases.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes, which could impact revenue stability. The company's operations are entirely within Thailand, and there is no indication of international expansion in the latest financial reports.

    Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The current fiscal year revenue of 20.75 billion THB is expected to remain relatively flat, with a marginal increase or decrease of less than 5% in the following year. This conservative outlook is supported by the company's capital structure and the current economic environment in Thailand.

    The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is low, with no significant dilution expected in the near term. The company has not issued additional shares recently, and there are no indications of a pending equity offering or share buyback program. The absence of dilution risk is a positive factor for shareholders, as it preserves ownership concentration and earnings per share.

    Recent events, including analyst estimates and recommendations, suggest a mixed outlook for the company. The mean price target of 3.86 THB and the median price target of 3.95 THB indicate a cautious but not overly optimistic view from analysts. The mean recommendation score of 3.23, with 8 hold ratings and 1 strong buy rating, reflects a generally neutral stance, with no strong consensus for either a buy or sell recommendation. These signals suggest that while the company is not expected to underperform significantly, it is also not seen as a high-growth opportunity in the near term.

    Key takeaways
    • Land and Houses PCL has a debt-to-equity ratio of 1.53, indicating a moderate reliance on debt financing.
    • The company's ROE of 7.16% is below the industry median, suggesting underperformance in equity utilization.
    • Free cash flow is negative at -2.57 billion THB, reflecting ongoing capital expenditures.
    • The company's revenue is concentrated in a single business segment with no geographic diversification.
    • Analysts have a generally neutral outlook, with a mean price target of 3.86 THB and a mean recommendation score of 3.23.
    • The company faces medium liquidity risk and low dilution risk, with no significant dilution expected in the near term.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $3,68
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $51.88B
    Net cash
    -$73.08B
    Current ratio
    1.9
    Debt / equity
    1.5
    ROA
    2.6%
    ROE
    7.2%
    Cash conversion
    171.0%
    CapEx / revenue
    -22.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Diagnostics78,0 %
    disclosed · sec_xbrl · 2025-12-31
    Biopharma Laboratory Services22,2 %
    disclosed · sec_xbrl · 2025-12-31

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology588,3B node revenueCVS 68,3%HCA 12,8%THC 3,6%UHS 3,0%LH 2,4%DVA 2,3%DGX 1,9%OPCH 1,0%Other 4,7%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)LH 2,4% · rank #5 of 28

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison7 peers · vs LH · multiples and returns
    CV
    CVS
    CVS HEALTH Corp
    $105,37
    134,8B USD
    P/E
    43,9x
    +14,4 vs self
    Div yield
    2,6 %
    +1,7 vs self
    ROE
    3,8 %
    -6,2 vs self
    HC
    HCA
    Hca Healthcare Inc
    $377,42
    85,5B USD
    P/E
    12,9x
    -16,6 vs self
    Div yield
    0,7 %
    -0,2 vs self
    ROE
    -107,6 %
    -117,7 vs self
    TH
    THC
    Tenet Healthcare Corp
    $249,99
    21,9B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    UH
    UHS
    Universal Health Services
    $169,04
    10,4B USD
    P/E
    6,3x
    -23,2 vs self
    Div yield
    0,5 %
    -0,4 vs self
    ROE
    19,9 %
    +9,9 vs self
    DV
    DVA
    Davita Inc
    $233,68
    16,1B USD
    P/E
    19,3x
    -10,2 vs self
    Div yield
    vs self
    ROE
    -98,9 %
    -108,9 vs self
    DG
    DGX
    Quest Diagnostics Inc
    $231,95
    26,0B USD
    P/E
    23,6x
    -5,9 vs self
    Div yield
    vs self
    ROE
    13,5 %
    +3,4 vs self
    OP
    OPCH
    Option Care Health Inc
    $22,09
    3,5B USD
    P/E
    16,5x
    -13,0 vs self
    Div yield
    vs self
    ROE
    15,5 %
    +5,5 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,32
    Predicted surprise
    -0,00
    Beat probability
    45 %
    Analysts
    13
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,32
    Revenueno estimateno estimate23,6B THB
    Operating incomeno estimateno estimate2,0B THB
    Full-year consensus mean (period as reported by source) · consensus in THB. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution13 analysts
    Strong buy1
    Buy0
    Hold8
    Sell3
    Strong sell1
    12-month price target$3,86 · Median $3,95
    Low $3,30High $4,50
    Operating income · consensus2,0B THB
    EPS surprise
    −4,1 %
    reported vs consensus · miss
    Revenue surprise
    −12,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$3,30
    Mean$3,86
    Median$3,95
    High$4,50
    Spot$3,68
    +4.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,8 %Below median
    Net Margin17,9 %Above median
    ROE7,2 %Above median
    Capex / Rev-22,0 %Bottom quartile
    D/E1,53Bottom quartile
    Cash Conv1,71Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 7 530 sh10 exercises8 insiders
    • Kyle Kathryn WEVP, Chief Legal Officer · Restricted Stock Unit → Common StockDisposed 256exercise · 2026-07-01
    • Vaughn Bryan TEVP and President, Diagnostics · Restricted Stock Unit → Common StockDisposed 327exercise · 2026-07-01
    • Wilkinson Peter JSVP, Chief Accounting Officer · Restricted Stock Unit → Common StockDisposed 536exercise · 2026-02-11
    • Schechter Adam HDirector, President & CEO · Restricted Stock Unit → Common StockDisposed 3 656exercise · 2026-02-11
    • Schroeder Mark SEVP, Pres Diagnostics & COO · Restricted Stock Unit → Common StockDisposed 806exercise · 2026-02-11
    • van der Vaart Sandra DEVP, Corporate Affairs · Restricted Stock Unit → Common StockDisposed 376exercise · 2026-02-11
    • Wang Julia AijunChief Financial Officer, EVP · Restricted Stock Unit → Common StockDisposed 860exercise · 2026-02-11
    • Vaughn Bryan TEVP, Diagnostics · Restricted Stock Unit → Common StockDisposed 323exercise · 2026-02-11
    • Wilkinson Peter JSVP, Chief Accounting Officer · Restricted Stock Unit → Common StockDisposed 160exercise · 2026-02-11
    • Summy Amy B.EVP, Chief Marketing Officer · Restricted Stock Unit → Common StockDisposed 230exercise · 2026-02-11

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Land and Houses PCL Market data — financials · 2026-05-28
    • Land and Houses PCL Market data — analyst estimates · 2026-05-28
    • Land and Houses PCL Market data — ESG · 2026-05-28

    Ownership & reference

    Leadership

    • Naporn SunthornchitcharoenExecutive Chairman of the Board

    Insider activity

    Net selling0 buys · 11 sellsnet -$7,2M13 insiders · last 365d
    • Vaughn Bryan TEVP and President, Diagnostics · Common StockSold 234 @ $286,19$67K · 2026-07-02
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockSold 92 @ $286,19$26K · 2026-07-02
    • Vaughn Bryan TEVP and President, Diagnostics · Common StockOther 93 @ $283,88$26K · 2026-07-01
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockOther 256 · 2026-07-01
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockOther 73 @ $283,88$21K · 2026-07-01
    • Vaughn Bryan TEVP and President, Diagnostics · Common StockOther 327 · 2026-07-01
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockSold 762 @ $263,89$201K · 2026-06-08
    • Schechter Adam HDirector, President & CEO · Common StockSold 5 903 @ $254,50$1,5M · 2026-05-11
    • Wilkinson Peter JSVP, Chief Accounting Officer · Common StockSold 1 633 @ $267,05$436K · 2026-03-27
    • Meltzer Jonathan CEVP, Operations · Common StockSold 839 @ $267,05$224K · 2026-03-27
    • Meltzer Jonathan CEVP, Operations · Common StockOther 2 388 · 2026-03-26
    • Meltzer Jonathan CEVP, Operations · Common StockOther 711 @ $268,38$191K · 2026-03-26
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockOther 1 584 · 2026-03-26
    • Kyle Kathryn WEVP, Chief Legal Officer · Common StockOther 451 @ $268,38$121K · 2026-03-26
    • Bailey Megan D.EVP, Pres, Central Labs & Intl · Common StockOther 1 184 · 2026-03-26
    • Schroeder Mark SEVP, Pres Diagnostics & COO · Common StockOther 9 304 · 2026-03-26
    • Bailey Megan D.EVP, Pres, Central Labs & Intl · Common StockOther 481 @ $268,38$129K · 2026-03-26
    • Schroeder Mark SEVP, Pres Diagnostics & COO · Common StockOther 4 600 @ $268,38$1,2M · 2026-03-26
    • Schroeder Mark SEVP, Pres Diagnostics & COO · Common StockOther 2 968 · 2026-03-26
    • Schroeder Mark SEVP, Pres Diagnostics & COO · Common StockOther 1 468 @ $268,38$394K · 2026-03-26
    • Caveney Brian JEVP, Pres of ED, CMO & CSO · Common StockOther 9 304 · 2026-03-26
    • Caveney Brian JEVP, Pres of ED, CMO & CSO · Common StockOther 4 042 @ $268,38$1,1M · 2026-03-26
    • Caveney Brian JEVP, Pres of ED, CMO & CSO · Common StockOther 1 986 · 2026-03-26
    • Caveney Brian JEVP, Pres of ED, CMO & CSO · Common StockOther 863 @ $268,38$232K · 2026-03-26
    • Wilkinson Peter JSVP, Chief Accounting Officer · Common StockOther 2 388 · 2026-03-26

    Short positioning

    2.7Mshares short-3.8% vs prior
    4.73days to cover
    52.9%short of daily vol
    60fails-to-deliver
    as of 2026-07-15 · short-interest report (free)
    Index membership
    S&P 500United States

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LH.BKCanonical
    SET (Bangkok) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): 10.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
    • Net margin (FY 2025-12-31): 6.3%Derived (calculated)
    • Gross margin (FY 2025-12-31): 28.8%Derived (calculated)
    • Return on assets (FY 2025-12-31): 4.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.42xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.13xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -11.3%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -65.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 5.9%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 18.3%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 10.7%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -4.6%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 17.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 27.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -5.4%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 7.2%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.1%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES 11SEC XBRL filing
    • Operating cash flow (annual): USD 1.64BSEC XBRL filing
    • Interest expense (annual): USD 224.1MSEC XBRL filing
    • Revenue (annual): USD 13.95BSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-09-11EVENTUpcomingDividend USD 0.72/sh
    2026-07-31 04:36 UTCFILINGMaterial 8-K
    2026-07-30 07:40 UTCEVENTEarnings Window
    2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-30EVENTQ2 2026 earnings (expected) estimated date
    2026-07-12 06:15 UTCNEWSOswal Overseas exits insolvency threat after ₹2.8 crore settlement with LH Sugar → NCLAT permits withdrawal of proceedings, removing a key legal overhang for the agri-trader. The resolution follows a broader wave of corporate distress cases in India's commodity sector.
    2026-07-02INSIDERVaughn Bryan T sold 234 sh — EVP and President, Diagnostics ~$67k
    2026-07-02INSIDERKyle Kathryn W sold 92 sh — EVP, Chief Legal Officer ~$26k
    2026-07-01INSIDERVaughn Bryan T transacted 93 sh — EVP and President, Diagnostics ~$26k
    2026-07-01INSIDERKyle Kathryn W transacted 256 sh — EVP, Chief Legal Officer
    2026-07-01INSIDERKyle Kathryn W transacted 73 sh — EVP, Chief Legal Officer ~$21k
    2026-07-01INSIDERVaughn Bryan T transacted 327 sh — EVP and President, Diagnostics
    2026-07-01INSIDERKyle Kathryn W disposed of 256 sh Restricted Stock Unit — EVP, Chief Legal Officer
    2026-07-01INSIDERVaughn Bryan T disposed of 327 sh Restricted Stock Unit — EVP and President, Diagnostics
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-08 00:00 UTCINSIDER1 insider transaction — 2026-06 · net sell $201k
    2026-06-08 00:00 UTCINSIDER1 insider transaction — 2026-06 · net sell $201k
    2026-06-08INSIDERKyle Kathryn W sold 762 sh — EVP, Chief Legal Officer ~$201k
    2026-05-27FILING8-K filing →
    2026-05-26FILING8-K filing →
    2026-05-11 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $1.5M
    2026-05-11 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $1.5M
    2026-05-11INSIDERSchechter Adam H sold 5.9k sh — Director, President & CEO ~$1.50M
    2026-05-04FILING10-Q filing →
    2026-05-01 08:53 UTCFILINGRegulatory filing →
    2026-04-30FILING8-K filing →
    2026-04-10FILINGDEF 14A filing →
    2026-04-09FILING8-K filing →
    2026-03-31FILING8-K filing →
    2026-03-27 00:00 UTCINSIDER31 insider transactions — 2026-03 · net sell $15.9M
    2026-03-27 00:00 UTCINSIDER31 insider transactions — 2026-03 · net sell $15.9M
    2026-03-27INSIDERWilkinson Peter J sold 1.6k sh — SVP, Chief Accounting Officer ~$436k
    Showing the 40 most recent of 82 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage